Background
==========

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer (NMSC) globally, with a constantly increasing incidence \[[@b1-medscimonit-22-3658],[@b2-medscimonit-22-3658]\]. The known risk factors for cSCC include aging, fair complexion, homosexual intercourse, chronic skin ulcers, burn scars, immune suppression, and exposure to ultraviolet light and chemical carcinogens \[[@b3-medscimonit-22-3658]\]. The vast majority of cSCCs are curable with simple surgical resection, and prognosis is usually favorable \[[@b4-medscimonit-22-3658]\]. However, approximately 4% of the patients develop metastatic disease and 1.5% eventually die from the disease \[[@b5-medscimonit-22-3658]\]. Metastatic cSCCs present serious therapeutic problems due to lack of consistently effective treatments \[[@b6-medscimonit-22-3658]\]. There are few treatments for patients with advanced cSCCs, primarily due to the lack of knowledge regarding genomic alternations that induce metastatic cSCC. Furthermore, there are no specific molecular biomarkers predict treatment response or disease behavior \[[@b4-medscimonit-22-3658]\]. Therefore, it is important to identify specific molecules involved in metastatic cSCC that can potentially become targets for diagnosis and enable the development of new therapy strategies.

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a key role in tumor development, invasion, and metastases formation \[[@b7-medscimonit-22-3658],[@b8-medscimonit-22-3658]\]. Angiogenesis is a complicated process stimulated by a variety of factors, among which vascular endothelial growth factor (*VEGF*) is crucial \[[@b9-medscimonit-22-3658]\]. *VEGF* is one of the most potent endothelial cell growth factors; it promotes formation of new blood vessels and stimulates vascular permeability of endothelial cells \[[@b10-medscimonit-22-3658]\]. *VEGF* initiates intracellular signal transduction pathways by specifically binding 2 transmembrane *VEGF* receptors on endothelial cells \[[@b11-medscimonit-22-3658]\]. While initiating intracellular signal transduction pathways, *VEGF* supplies the newly formed blood vessels with nutrients and oxygen. This induces aggressive local growth and metastases formation, resulting in poor prognosis and low survival rates of cancer patients \[[@b12-medscimonit-22-3658]\].

The *VEGF* gene is located at chromosome 6p21.3 and consists of 8 exons and 7 introns. It is very polymorphic, with at least 30 functional single-nucleotide polymorphisms (SNPs) in the 5′-untranslated region, 3′-untranslated region (UTR) and promoter \[[@b13-medscimonit-22-3658]\]. Single-nucleotide polymorphisms (SNPs) of *VEGF* that can be found in the promoter or other regulatory regions may regulate *VEGF* expression or activity \[[@b14-medscimonit-22-3658]\]. The involvement of *VEGF* polymorphisms in cancer progression has been demonstrated in several types of tumors \[[@b15-medscimonit-22-3658]--[@b18-medscimonit-22-3658]\]. *VEGF* polymorphisms have previously been described in solid carcinomas, containing lung cancer \[[@b7-medscimonit-22-3658],[@b19-medscimonit-22-3658]\], non-Hodgkin's lymphoma \[[@b20-medscimonit-22-3658]\], cervical cancer \[[@b21-medscimonit-22-3658]\], colorectal cancer \[[@b22-medscimonit-22-3658]\], esophageal squamous cell carcinoma (ESCC) \[[@b10-medscimonit-22-3658], [@b23-medscimonit-22-3658]\], and oral squamous cell carcinoma (OSCC) \[[@b9-medscimonit-22-3658],[@b24-medscimonit-22-3658]--[@b26-medscimonit-22-3658]\]. The impact of the VEGF SNPs on clinical outcomes of patients with cancer has been previously described \[[@b7-medscimonit-22-3658],[@b12-medscimonit-22-3658],[@b26-medscimonit-22-3658],[@b27-medscimonit-22-3658]\]. However, the impact of *VEGF* polymorphism during follow-up has been much less studied. The -*1154*460C\>T SNP (rs833061) and -1154G\>A SNP (rs1570360) are located at the promoter region and may regulate promoter activity. The association of these 2 functional SNPs with OSCC risk has been previously studied \[[@b9-medscimonit-22-3658],[@b12-medscimonit-22-3658]\]. However, the effect of *VEGF* gene -460C\>T SNP (rs833061) and -1154G\>A SNP (rs1570360) on cSCC risk and prognosis remains unclear \[[@b28-medscimonit-22-3658],[@b29-medscimonit-22-3658]\].

In the current study, the -460C\>T SNP (rs833061) and -1154G\>A SNP (rs1570360) within the *VEGF* gene were detected in cSCC patients; a regular follow-up was conducted for all the patients. This study aimed to further clarify the potential association of these 2 SNPs with the cSCC risk and to evaluate the prognostic impact of *VEGF*-related SNPs on cSCC patients.

Material and Methods
====================

Study population
----------------

This study consisted of 100 patients with cSCC. They were treated in the department of Surgery at Shandong Provincial Hospital Affiliated to Shandong University between 2010 and 2014; the group included 55 men and 45 women. The ages of patients ranged from 34 to 76 years old, with the average age of 56.04±10.41 years old. No patients underwent radiotherapy, chemotherapy, or hormone therapy before surgery. The control group contained 124 healthy subjects who came from our hospital's physical checkup center during the same period of time. All control subjects had no history of blood system disease or cancer. Written permission was obtained from all the participants and the study was approved by the Research Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University.

DNA extraction
--------------

Peripheral venous blood samples (5 mL) were acquired from all the participants and stored at −20°C until the extraction of genomic DNA. Genomic DNA was isolated with the QIAamp DNA mini kit (Qiagen, Hamburg Germany) according to the manufacturer's protocol. The extracted DNA was stored at −80°C for further use.

Detection of VEGF gene polymorphism
-----------------------------------

Genotyping of the *VEGF* gene -460C\>T and -1154G\>A polymorphisms were detected using PCR -- RFLP method. The primers of -*1154*460C\>T were 5′-CGAGAGTGAGGACGTGTGTG-3′(forward) and 5′-ATTGGAATCCTGGAGTGACC-3′(reverse); the primers for -*1154*1154G\>A were 5′-TCCTGCTCCCTCCTCGCCAATG-3′(forward) and 5′-GGCGGGGACAGGCGAGCATC-3′(reverse), purchased from Sangon Biotech (Shanghai, China). The PCR reaction was performed in a 20-μl reaction mixture containing 40--160 ng DNA template, 0.25 units *Taq* DNA polymerase (Sangon Biotech), 250 μM each deoxyribonucleotide triphosphate (dNTP) (Sangon Biotech), 0.5 μM forward primer, 0.5 μM reverse primer, and 1×PCR buffer with 1.2 mM MgCl~2~. A negative control without DNA template was used to evaluate contamination. The PCR reaction was carried out in a thermocycler (MJ Research, USA) and reaction conditions consisted of 94 °C pre-denaturizing for 5 min, 94°C denaturizing for 45 s, 61°C annealing for 45 s, 72°C extension for 45 s, and 72°C continuous extension for 7 min after 35 cycles. The amplified products were digested with Bshl236I and MnlI restriction endonuclease (Takara, Japan) incubated at 37°C for 16 h. The PCR and digestion products were analyzed with 3% agarose gels.

Follow-up
---------

Follow-up files were created for all the cSCC patients upon admission, including complete pathological, clinical, and follow-up data. A regular follow-up of 2\~5 years for 100 patients was performed by hospital visit, treatment, and telephone interview. Follow-up start time was defined as the discharge time of patients after system treatment and the follow-up deadline was January 2015. Follow-up time was counted monthly until death or the end of the follow-up time.

Statistical analysis
--------------------

All statistical analyses in this study were performed by SPSS 19.0 software packages. Differences between ages were analyzed with unpaired t-tests. Counted data were analyzed with the chi-square test. Hardy-Weinberg equilibrium (HWE) was calculated with Hardy-Weinberg equilibrium theory (*p*=allele frequency, *q*=1--*p*, *p*^2^+*q*^2^=1). The different distributions of allele frequencies and genotypes in the case and control group were analyzed using the chi-square test. Logistic regression analysis was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). Kaplan-Meier method was used to plot survival curves and the statistical differences were analyzed with the log-rank test. *P* value \<0.05 was defined as statistically significant.

Results
=======

General research characteristics
--------------------------------

The patient group consisted of 100 cSCC cases. There were 55 men and 45 women in the patient group; 46 patients were under 60 years old and 54 patients were 60 years old or older (average age: 56.04±10.41 years old; range: 34--76 years old). There were 40 poorly-differentiated cases (the percentage of differentiated cells \<50%), 34 moderately-differentiated cases (the differentiated cells between 50--75%), and 26 well-differentiated cases (the differentiated cells \>75%), according to Broders classification \[[@b30-medscimonit-22-3658]\]. Thirty-five cases with lymph node involvement and 65 cases without lymph node involvement were identified. The control group contained 124 healthy subjects attending the hospital physical checkup center during the same period. There were 66 males and 58 females in the control group; 59 subjects were under 60 years old and 65 patients were 60 years old or older (average age: 53.79±11.89 years; range: 30--78 years). Age and sex in the two groups showed no significant differences (*P*\>0.05) ([Table 1](#t1-medscimonit-22-3658){ref-type="table"}).

Genotyping of the VEGF gene -460C\>T and -1154G\>A polymorphisms
----------------------------------------------------------------

Genotypes of the *VEGF*-460C\>T and -1154G\>A were successfully detected in all the DNA samples using the PCR-RFLP method. The 175-bp PCR product of *VEGF*-460C\>T was digested with Bshl236I restriction endonuclease. The homozygous T/T genotype remained uncut at 175bp; the homozygous C/C genotype was completely digested into 155 bp and 20 bp fragments; 175 bp, 155 bp, and 20 bp fragments corresponded to the heterozygous C\>T genotype ([Figure 1](#f1-medscimonit-22-3658){ref-type="fig"}). The 206-bp PCR product of *VEGF*-1154G\>A was digested with MnlI restriction endonuclease and the G allele was replaced by the A allele with a loss of digestion site*.* The homozygous A/A genotype was digested into 184bp and 22bp fragments; the homozygous G/G genotype was completely digested into 150 bp, 34 bp and 22 bp fragments; all 4 fragments (184 bp, 150 bp, 34bp, and 22 bp) corresponded to the heterozygous G\>A genotype ([Figure 2](#f2-medscimonit-22-3658){ref-type="fig"}).

The association between clinicopathological characteristics and VEGF polymorphism
---------------------------------------------------------------------------------

The distribution of the *VEGF*-460C\>T SNP genotype in patients is presented in [Table 2](#t2-medscimonit-22-3658){ref-type="table"}. The genotype frequencies of CC, CT, and TT in the well-differentiated group was 46.15%, 38.46%, and 15.38%, respectively; in the moderately-differentiated group, the genotype frequencies of CC and CT were 44.11% and 55.89%, respectively; the genotype frequencies of CC and CT were 95.00% and 5.00%, respectively, in the poorly-differentiated group. There were hardly any carriers of homozygote TT in either moderately- or poorly-differentiated grades. Differences between the 3 groups were significant (*P*\<0.001). The genotype distribution of *VEGF*-1154 G\>A was also associated with histological differentiation of cSCC (*P*\<0.001). The genotype frequencies of GG in the well-differentiated group, the moderately-differentiated group, and the poorly-differentiated group were 96.15%, 47.06%, and 25.00%, respectively; the genotype frequencies of GA in the well-differentiated group, the moderately-differentiated group, and the poorly-differentiated group were 4.00%, 47.06%, and 60.00%, respectively. The genotype distribution of *VEGF*-460C\>T and *VEGF*-1154 G\>A showed no significant correlation with age, sex, or lymph node metastasis (all *P*\>0.05) ([Table 2](#t2-medscimonit-22-3658){ref-type="table"}).

The genotype and allele distribution of VEGF-460C\>T and -1154G\>A SNP
----------------------------------------------------------------------

The *VEGF*-460C\>T and -1154G\>A genotype and allele distribution of the cSCC patients and of the control group are presented in [Table 3](#t3-medscimonit-22-3658){ref-type="table"}. The genotype distribution of the *VEGF*-460C\>T and -1154G\>A polymorphism did not deviate from Hardy-Weinberg equilibrium (*P*\>0.05). The CT and CC genotype frequencies of *VEGF*-460C\>T in the control group were 50.81% and 41.13%, which were significantly different from those in the patient group (31.00% and 65.00%, respectively) (CT *vs.* CC, OR=0.39, 95%CI: 0.22--0.68, *P*=0.001). Compared to the CC genotype, the TT+CT genotype significantly decreased the risk of cSCC (OR=0.36, 95% CI: 0.21--0.63, *P*\<0.001). The C allele frequencies in the control group and patient group were 66.53% and 80.50%, respectively; while the T allele frequencies in the control group and patient group were 33.47% and 19.50%, respectively; the differences in the 2 groups were statistically significant (T *vs.* C, OR=0.48, 95%CI: 0.31--0.75, *P*=001). Comparing the genotype distributions of the *VEGF* gene -1154 G\>A polymorphism in cSCC patients to that in the controls revealed no significant differences (*P*\>0.05) and the differences in allele frequencies were also not statistically significant.

VEGF gene -460C\>T and -1154G\>A polymorphism and the prognosis of cSCC
-----------------------------------------------------------------------

A systematic follow-up of 2\~5 years for 100 cSCC patients was performed. The follow-up deadline was January 2015; the longest follow-up time was 60 months and the shortest follow-up time was 24 months. Eleven patients were lost during the follow-up period; the follow-up rate was 89%. For *VEGF*-460C\>T SNP, the mean survival time of cSCC patients with CC, CT, and TT genotype were 28.92, 53.54, and 58.75 months, respectively. The CC genotype was an adverse factor that negatively affected the survival time of cSCC patients when compared with heterozygote CT and homozygote TT (*P*\<0.001, [Figure 3](#f3-medscimonit-22-3658){ref-type="fig"}). For *VEGF*-1154 G\>A SNP, the mean survival time of cSCC patients with GG, GA, and AA genotypes were 41.19, 36.41, and 23.88 months, respectively; compared to the GG and GA genotypes, the AA genotype had a significant correlation with decreased overall survival time (*P*=0.009, [Figure 4](#f4-medscimonit-22-3658){ref-type="fig"}).

Discussion
==========

Angiogenesis is an important process for tumor development, invasion, and metastasis; it is stimulated by a variety of factors. *VEGF* is considered to be one of the key factors involved \[[@b7-medscimonit-22-3658],[@b8-medscimonit-22-3658]\]. Recently, several *VEGF* SNPs have been identified and their important effects have attracted considerable attention. Correlation between *VEGF* SNPs and susceptibility or prognosis in various forms of cancers has been reported in many studies \[[@b7-medscimonit-22-3658],[@b10-medscimonit-22-3658],[@b25-medscimonit-22-3658],[@b31-medscimonit-22-3658]\]. In the present study, the -460 C\>T and -1154 G\>A polymorphisms of *VEGF* in 100 cSCC patients and 124 healthy subjects were observed. In order to analyze the relation of *VEGF* gene polymorphisms with cSCC risk, the patients were stratified by age, sex, histopathological grade, and lymph node involvement. The results demonstrate that the genotype distribution of *VEGF*-460 C\>T shows no correlation with age, sex, or lymph node metastasis (all *P*\>0.05), but there was association with histological differentiation of cSCC (*P*\<0.001). A significant difference was found between the genotype distribution and allele frequency of the *VEGF* gene -460 C\>T polymorphism of the control group and that of the patients with cSCC. Furthermore, a higher percentage of the T allele and the TT homozygote were distributed in cSCC patients compared to the controls. Therefore, we can reason that there was a much lower cSCC risk for individuals with the CT heterozygote genotype in their *VEGF*-460 C\>T region, indicating that the *VEGF*-460 C\>T polymorphism could act as a candidate genetic biomarker in cSCC patients. The association of the *VEGF*-460 C\>T polymorphism with clinical outcomes in cSCC patients has not been evaluated. However, there were several studies concerning *VEGF*-460 C\>T polymorphism in other cancers. For example, Ku et al. indicated that the T allele and TT genotype of *VEGF*-460 C\>T are significantly associated with OSCC \[[@b32-medscimonit-22-3658]\]. Borase et al. demonstrated that the T allele and TT genotype of *VEGF*-460 C\>T can greatly increase the risk for OSCC patients \[[@b26-medscimonit-22-3658]\]. In the analysis of a correlation between clinical characteristics and the *VEGF* gene -1154 G\>A polymorphism, the results demonstrate that the genotype distribution of *VEGF*-1154 G\>A shows no relation with age, sex, or lymph node metastasis (all *P*\>0.05), but there was an association with histological differentiation of cSCC (*P*\<0.001). The decreased frequency of the *VEGF*-1154 A allele (AA and GA genotypes) in cSCC patients did not differ significantly from that of the control. In a previous study, Kämmerer et al. demonstrated that the genotype distribution of *VEGF*-1154 G\>A in OSCC patients and controls had no significant difference \[[@b9-medscimonit-22-3658]\]. Unal et al. examined 89 healthy subjects and 57 patients with laryngeal squamous cell carcinoma; they found that the -1154 GG genotype of *VEGF* appears to be a higher risk for laryngeal SCC patients \[[@b33-medscimonit-22-3658]\].

Prognostic factors play an essential role when come to dividing patients into different risk groups in order to predict outcomes and provide adequate therapy strategies \[[@b34-medscimonit-22-3658]\]. In the current study, the relationship between *VEGF* gene -460 C\>T polymorphism, -1154 G\>A polymorphism, and the survival of patients with cSCC was examined for the first time. The results demonstrate that the TT genotype of -460 C\>T is a protective factor in comparison to genotypes of CT and CC, positively affecting the survival time of cSCC patients (*P*\<0.001). The AA genotype of -1154 G\>A has a significant correlation with the decreased overall survival time in cSCC patients when compared with homozygote GG and heterozygote GA (*P*=0.009).

The association of *VEGF* gene polymorphism with survival was controversial in previous studies. Kämmerer et al. observed that the *VEGF*-460 C\>T SNP had no significant impact on survival in advanced OSCCs, while the -1154 AA genotype was associated with significantly worse survival in the univariate analysis \[[@b12-medscimonit-22-3658]\]. In contrast, Supic et al. found that the -1154 GG genotype may be a prognostic marker associated with significantly worse survival in advanced-stage OSCC patients with a similar sample size \[[@b8-medscimonit-22-3658]\]. Other studies revealed the -1154 GG genotype to be an adverse survival factor in colorectal cancer \[[@b35-medscimonit-22-3658]\], but it was associated with a higher overall survival of the 1154 A allele in advanced breast cancer \[[@b36-medscimonit-22-3658]\]. To sum up, results of clinical studies are inconsistent, possibly due to differences in ethnic groups studied, tumor locations, and sample sizes.

In this study, only 2 SNPs in the promoter were analyzed, which might be a limiting factor. The results of 1 specific SNP may be influenced by the other SNPs in the angiogenesis pathway. In addition, the sample sizes of the present study are somewhat small, even though similar studies were previously performed \[[@b26-medscimonit-22-3658],[@b33-medscimonit-22-3658]\]. Hence, more studies, including larger sample sizes and more SNPs, distributed not only in the promoter but also in the 5′ and 3′ un-translated region, should be conducted.

Conclusions
===========

Our data suggest that the *VEGF* gene -460 C\>T polymorphism is related to the risk of cSCC, and both *VEGF* gene -460 C\>T polymorphism and -1154 G\>A polymorphism are correlated with the prognosis of cSCC patients. Therefore, the *VEGF* gene -460 C\>T polymorphism and -1154 G\>A polymorphism may serve as a potential genetic marker for the risk and prognosis of cSCC.
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![*VEGF*-460C\>T genotyping by PCR-RFLP analysis followed by separation on 3% agarose gel as described in text. M -- 100 bp DNA marker; lanes 1, 5 and 8 -- T/T homozygous genotype; lanes 2, 4 and 9 -- C\>T heterozygous genotype; lanes 3, 6 and 7 -- C/C homozygous genotype; lane 10 -- PCR product.](medscimonit-22-3658-g001){#f1-medscimonit-22-3658}
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###### 

Characteristics of patients with CSCC and control group.

  Characteristics                  CSCC (n=100)   Controls (n=124)   *P*-value
  -------------------------------- -------------- ------------------ -----------
  Age (years old), n (%)                                             
  Mean ±SD                         56.04±10.41    53.79±11.89        0.138
   ≥60                             54 (54.00%)    65 (52.42%)        
   \<60                            46 (46.00%)    59 (47.58%)        
  Sex, n (%)                                                         
   Male                            55 (55.00%)    66 (53.23%)        0.836
   Female                          45 (45.00%)    58 (46.77%)        
  Histopathological grade, n (%)                                     
   Well-differentiated             26 (26.00%)                       
   Moderately-differentiated       34 (34.00%)                       
   Poorly-differentiated           40 (40.00%)                       
  Lymph node involvement, n (%)                                      
   Yes                             35 (35.00%)                       
   No                              65 (65.00%)                       

CSCC -- cutaneous squamous cell carcinoma; SD -- standard deviation.

###### 

Correlations between clinicopathological characteristics and *VEGF* polymorphisms.

  Characteristics              n    -460C\>T   *P*-value   -1154G\>A   *P*-value                 
  ---------------------------- ---- ---------- ----------- ----------- ----------- ---- ---- --- ---------
  Age (years)                                                          0.858                     0.128
   ≥60                         54   34         18          2                       24   25   2   
   \<60                        46   31         13          2                       27   16   6   
  Sex                                                                  0.908                     0.124
   Male                        55   35         18          2                       33   19   3   
   Female                      45   30         13          2                       18   22   5   
  Histopathological grade                                              \<0.001                   \<0.001
   Well-differentiated         26   12         10          4                       25   1    0   
   Moderately-differentiated   34   15         19          0                       16   16   2   
   Poorly-differentiated       40   38         2           0                       10   24   6   
  Lymph node involvement                                               0.606                     0.141
   Yes                         35   25         9           1                       22   11   2   
   No                          65   40         22          3           29          30   6        

###### 

*VEGF* genotype and allele frequency in patients with cSCC (n=100) and control (n=124).

  Groups               Controls (n=124)   Patients (n=100)   *P*-value[\*](#tfn3-medscimonit-22-3658){ref-type="table-fn"}   OR (95% CI)         *P*-value[\#](#tfn4-medscimonit-22-3658){ref-type="table-fn"}
  -------------------- ------------------ ------------------ --------------------------------------------------------------- ------------------- ---------------------------------------------------------------
  **-1154460 C\>T**                                                                                                                              
   CC                  51 (41.13%)        65 (65.00%)        --                                                              1.00 (reference)    --
   CT                  63 (50.81%)        31 (31.00%)        0.001                                                           0.39 (0.22--0.68)   0.043
   TT                  10 (8.06%)         4 (4.00%)          0.052                                                           0.31 (0.09--1.06)   0.715
   TT+CT               73 (58.87%)        35 (35.00%)        \<0.001                                                         0.36 (0.21--0.63)   \<0.001
  Allele frequency                                                                                                                               
   C                   165 (66.53%)       161 (80.50%)       --                                                              1.00 (reference)    --
   T                   83 (33.47%)        39 (19.50%)        0.001                                                           0.48 (0.31--0.75)   --
  **-11541154 G\>A**                                                                                                                             
   GG                  54 (43.55%)        51 (51.00%)        --                                                              1.00 (reference)    --
   GA                  58 (46.77%)        41 (41.00%)        0.305                                                           0.75 (0.43--1.30)   0.247
   AA                  12 (9.68%)         8 (8.00%)          0.482                                                           0.71 (0.27--1.87)   0.654
   GA+AA               70 (56.45%)        49 (49.00%)        0.267                                                           0.74 (0.44--1.26)   0.155
  Allele frequency                                                                                                                               
   G                   166 (66.94%)       143 (71.50%)       --                                                              1.00 (reference)    --
   A                   82 (33.06%)        57 (28.50%)        0.299                                                           0.81 (0.54--1.21)   --

*VEGF* -- vascular endothelial growth factor; OR -- odds ratio; CI -- confidence interval.

Two-sided χ^2^ test for distribution of genotypic and allelic frequencies.

Compared by binary logistic multivariate regression model with adjustment of sex and age for cases and controls.
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